Evidence map›Paper›PMID 35468938›Full record

ArticleOncogene2022

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.

Shan Zhu, Chunliu Zhang, Dongyan Cao, Jing Bai, Shuangni Yu, Jie Chen, Jing Wang, Tong Ren, Jiaxin Yang, Mei Yu and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 2 countries.

Shan Zhu *Department of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chunliu Zhang *Geneplus institute, Beijing, China.ORCID http://orcid.org/0000-0002-7433-1529
Dongyan CaoDepartment of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing BaiGeneplus institute, Beijing, China.
Shuangni YuDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Jie ChenDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Jing WangDepartment of Gynecology Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Tong RenDepartment of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiaxin YangDepartment of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Mei YuDepartment of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiao XiaoGeneplus-Shenzhen, Shenzhen, China.
Yuhua GongGeneplus institute, Beijing, China.
Yanfang GuanGeneplus institute, Beijing, China.
Peiling LiDepartment of Obstetrics and Gynecolgoy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID http://orcid.org/0000-0003-2040-4136
Ying YueDepartment of Gynecological Oncology, First Hospital of Jilin University, Changchun, China.
Rutie YinDepartment of Obstetrics and Gynecology, West China Second Hospital of Sichuan University, Chengdu, China.
Yongjun WangDepartment of Obstetrics and Gynecology, Peking University International Hospital, Beijing, China.
Ruifang AnDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Ge LouDepartment of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jianlin YuanDepartment of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Guonan ZhangDepartment of Gynecologic Oncology, Sichuan Cancer Hospital, Chengdu, China.
Xuefeng XiaGeneplus institute, Beijing, China.
Ling YangGeneplus institute, Beijing, China. yangl@geneplus.org.cn.ORCID http://orcid.org/0000-0002-6698-1214
Yang XiangDepartment of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xiangy@pumch.cn.ORCID http://orcid.org/0000-0002-9112-1021
Chinese Academy of Medical Sciences & Peking Union Medical College · CNHarbin Medical University · CNCentral South University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNGene Therapy Laboratory · FRJilin University · CNPeking University · CNShenzhen Bioeasy Biotechnology (China) · CNSichuan Cancer Hospital · CNSichuan University · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is classified into five major histotypes: high-grade serous (HGSOC), low-grade serous (LGSOC), clear cell (CCOC), endometrioid (ENOC), and mucinous (MOC). However, the landscape of molecular and immunological alterations in these histotypes, especially LGSOC, CCOC, ENOC, and MOC, is largely uncharacterized. We collected 101 treatment-naive EOC patients. The resected tumor tissues and paired preoperative peripheral blood samples were collected and subjected to target sequencing of 1021 cancer-associated genes and T cell repertoire sequencing. Distinct characteristics of mutations were identified among the five histotypes. Furthermore, tumor mutation burden (TMB) was found to be higher in CCOC and ENOC, but lower in LGSOC and HGSOC. Alterations associated with DNA damage repair (DDR) pathways and homologous recombination deficiencies (HRD) were prevalent in five histotypes. CCOC demonstrated increased level of T cell clonality compared with HSGOC. Interestingly, the proportion of the 100 most common T cell clones was associated with TMB and tumor neoantigen burden in CCOC, highlighting more sensitive anti-tumor responses in this histotype, which was also evidenced by the enhanced convergent recombination of T cell clones. These findings shed light on the molecular traits of genomic alteration and T cell repertoire in the five major EOC histotypes and may help optimize clinical management of EOC with different histotypes.

Indexed as

Ovarian NeoplasmsBiomarkers, TumorCarcinoma, Ovarian EpithelialFemaleGenomicsHumansPhenotypeReceptors, Antigen, T-CellBiomarkers, TumorReceptors, Antigen, T-Cell

Identifiers

PMID35468938
OpenAlexW4224943718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.